JQ
Therapeutic Areas
Mirum Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LIVMARLI (maralixibat) | Alagille Syndrome (ALGS) | Approved |
| Brelovitug | Chronic Hepatitis Delta Virus (HDV) | Phase 3 |
| Volixibat | Primary Sclerosing Cholangitis (PSC) | Phase 2b |
Leadership Team at Mirum Pharmaceuticals
CP
Chris Peetz
Chief Executive Officer
EB
Eric Bjerkholt
Chief Financial Officer
EC
Erin Campany
Chief People Officer
HJ
Hassan Javanbakht, Ph.D.
Chief Scientific Officer
JG
Jean-Luc Girardet, Ph.D.
Chief Technical Officer
VK
Vinita Kumar
Senior Vice President, Quality
LL
Lara Longpre
Chief Development Officer
PR
Peter Radovich
President & Chief Operating Officer
DS
Doug Sheehy, JD
Chief Legal Officer
NS
Nancy Shulman, M.D.
Executive Vice President, Clinical